Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

References

• Al-Tawfiq JA, Memish ZA. Managing MERS-CoV in the healthcare setting. Hosp Pr. 2015;43:158–163.
   PubMedGoogle Scholar
• Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369:407–416.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Perl TM. Middle East respiratory syndrome coronavirus in healthcare settings. Curr Opin Infect Dis. 2015;28:392–396.
   PubMed Web of Science ®Google Scholar
• WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) n d. Available from: http://www.who.int/emergencies/mers-cov/en/
   Google Scholar
• Momattin H, Mohammed K, Zumla A, et al. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)–possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis. 2013;17:e792–e798.
   PubMed Web of Science ®Google Scholar
• Oxford Centre for Evidence-based Medicine. Oxford centre for evidence-based medicine - levels of evidence (March 2009) – CEBM. 2009.[cited 2016 Sep 21]. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009
   Google Scholar
• Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67:606–616.
   PubMed Web of Science ®Google Scholar
• Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol. 2008;89:1–47.
   PubMed Web of Science ®Google Scholar
• Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95:571–577.
   PubMed Web of Science ®Google Scholar
• Falzarano D, de Wit E, Martellaro C, et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep. 2013;3:1686.
   PubMed Web of Science ®Google Scholar
• Adedeji AO, Sarafianos SG. Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection. Future Med Chem. 2013;5:2119–2122.
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212:1904–1913.
   PubMed Web of Science ®Google Scholar
• De Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58:4875–4884.
   PubMed Web of Science ®Google Scholar
• Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus (MERS-CoV) infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87:12552–12561.
   PubMed Web of Science ®Google Scholar
• Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067.
   PubMed Web of Science ®Google Scholar
• De Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol. 2013;94:1749–1760.
   PubMed Web of Science ®Google Scholar
• De Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011;92:2542–2548.
   PubMed Web of Science ®Google Scholar
• Rossignol J-F. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016;9:227–230.
   PubMed Web of Science ®Google Scholar
• Zhou N, Pan T, Zhang J, et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem. 2016;291:9218–9232.
   PubMed Web of Science ®Google Scholar
• Pan Q, De Ruiter PE, Metselaar HJ, et al. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C virus infection in vitro and in vivo. Hepatology. 2012;55:1673–1683.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Lu L, Xia S, et al. Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J Infect Dis. 2015;212:1894–1903.
   PubMed Web of Science ®Google Scholar
• Zhao J, Perera RAPM, Kayali G, et al. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol. 2015;89:6117–6120.
   PubMed Web of Science ®Google Scholar
• Agrawal AS, Ying T, Tao X, et al. Passive transfer of A Germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection. Sci Rep. 2016;6:31629.
   PubMed Web of Science ®Google Scholar
• Qiu H, Sun S, Xiao H, et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antiviral Res. 2016;132:141–148.
   PubMed Web of Science ®Google Scholar
• Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-alpha 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19:1313–+.
   PubMed Web of Science ®Google Scholar
• Ying T, Prabakaran P, Du L, et al. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun. 2015;6:8223.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Momattin H, Dib J, et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.. Int J Infect Dis. 2014;20:42–46.
   PubMed Web of Science ®Google Scholar
• Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14:1090–1095.
   PubMed Web of Science ®Google Scholar
• Khalid I, Alraddadi BM, Dairi Y, et al. Acute management and long-term survival among subjects with severe Middle East respiratory syndrome coronavirus pneumonia and ARDS. Respir Care. 2016;61:340–348.
   PubMed Web of Science ®Google Scholar
• Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70:2129–2132.
   PubMed Web of Science ®Google Scholar
• Al Ghamdi M, Alghamdi KM, Ghandoora Y, et al. Treatment outcomes for patients with Middle Eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis. 2016;16:174.
   PubMed Web of Science ®Google Scholar
• Kim UJ, Won E-J, Kee S-J, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report. Antivir Ther. 2015;21:455–459.
   PubMedGoogle Scholar
• Spanakis N, Tsiodras S, Haagmans BL, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents. 2014;44:528–532.
   PubMed Web of Science ®Google Scholar
• Khalid M, Al Rabiah F, Khan B, et al. Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. Antivir Ther. 2015;20:87–91.
   PubMed Web of Science ®Google Scholar
• Malik A, El Masry KM, Ravi M, et al. Middle East respiratory syndrome coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013. Emerg Infect Dis. 2016;22:515–517.
   PubMed Web of Science ®Google Scholar
• Khalid M, Khan B, Al Rabiah F, et al. Middle Eastern Respiratory Syndrome corona virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia. Ann Saudi Med. 2014;34:396–400.
   PubMed Web of Science ®Google Scholar
• Lee H, Ki C-S, Sung H, et al. Guidelines for the laboratory diagnosis of Middle East respiratory syndrome coronavirus in Korea. Infect Chemother. 2016;48:61–69.
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Haagmans BL, Hatano R, et al. Inhibition of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by anti-CD26 monoclonal antibody. J Virol. 2013;87:13892–13899.
   PubMed Web of Science ®Google Scholar
• Pascal KE, Coleman CM, Mujica AO, et al. Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci. 2015;112:8738–8743.
   PubMed Web of Science ®Google Scholar
• Du L, Kou Z, Ma C, . A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One. 2013;8:e81587.
   Web of Science ®Google Scholar
• Du L, Zhao G, Yang Y, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol. 2014;88:7045–7053.
   PubMed Web of Science ®Google Scholar
• Li Y, Wan Y, Liu P, et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 2015;25:1237–1249.
   PubMed Web of Science ®Google Scholar
• Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med. 2014;6:234ra59.
   PubMed Web of Science ®Google Scholar
• Tang X-C, Agnihothram SS, Jiao Y, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA. 2014;111:E2018–E2026.
   PubMed Web of Science ®Google Scholar
• Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014;88:7796–7805.
   PubMed Web of Science ®Google Scholar
• Mou H, Raj VS, van Kuppeveld FJM, et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol. 2013;87:9379–9383.
   PubMed Web of Science ®Google Scholar
• Johnson RF, Bagci U, Keith L, et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology. 2016;490:49–58.
   PubMed Web of Science ®Google Scholar
• Corti D, Zhao J, Pedotti M, et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci USA. 2015;112:10473–10478.
   PubMed Web of Science ®Google Scholar
• Luke T, Wu H, Zhao J, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016;8:326ra21.
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254.
   PubMed Web of Science ®Google Scholar
• Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500:227–231.
   PubMed Web of Science ®Google Scholar
• Lambeir A-M, Durinx C, Scharpé S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209–294.
   PubMed Web of Science ®Google Scholar
• Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol. 2003;82:53–73.
   PubMed Web of Science ®Google Scholar
• Hung IF, To KK, Lee C-K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–456.
   PubMed Web of Science ®Google Scholar
• Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599–609.
   PubMed Web of Science ®Google Scholar
• Wu -X-X, Gao H-N, Wu H-B, et al. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis. 2015;41:3–5.
   PubMed Web of Science ®Google Scholar
• Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006;12:489.
   PubMedGoogle Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160:389–397.
   PubMed Web of Science ®Google Scholar
• Kapoor M, Pringle K, Kumar A, et al. Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) into the United States. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2014;59:1511–1518.
   PubMed Web of Science ®Google Scholar
• Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4:709.
   PubMed Web of Science ®Google Scholar
• Alshukairi AN, Khalid I, Ahmed WA, et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis. 2016;22. DOI:10.3201/eid2206.160010
   Web of Science ®Google Scholar
• Drosten C, Meyer B, Müller MA, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014;371:828–835.
   PubMed Web of Science ®Google Scholar
• Corman VM, Albarrak AM, Omrani AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis. 2015.
   Web of Science ®Google Scholar
• Park WB, Perera RAPM, Choe PG, et al. Kinetics of serologic responses to mers coronavirus infection in humans, South Korea. Emerg Infect Dis. 2015;21:2186–2189.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22:1554–1561.
   PubMed Web of Science ®Google Scholar
• Long Y, Xu Y, Wang B, et al. Clinical recommendations from an observational study on MERS: glucocorticoids was benefit in treating SARS patients. Int J Clin Exp Med. 2016;9:8865–8873.
   Web of Science ®Google Scholar
• Auyeung T, Lee J, Lai W, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005;51:98–102.
   PubMed Web of Science ®Google Scholar
• Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304–309.
   PubMed Web of Science ®Google Scholar
• The Who Mers-Cov Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr. 2013;5:1–30.
   Google Scholar
• Belouzard S, Millet JK, Licitra BN, et al. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4:1011–1033.
   PubMed Web of Science ®Google Scholar
• Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58:4885–4893.
   PubMed Web of Science ®Google Scholar
• Uyeki TM, Erlandson KJ, Korch G, et al. Development of medical countermeasures to Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22. DOI:10.3201/eid2207.160022
   Web of Science ®Google Scholar
• Sakamoto S, Tanaka H, Morimoto S. Towards the prophylactic and therapeutic use of human neutralizing monoclonal antibodies for Middle East respiratory syndrome coronavirus (MERS-CoV). Ann Transl Med. 2015;3:35.
   PubMedGoogle Scholar
• Modjarrad K Research and development activities for Middle East respiratory syndrome: The Current Landscape. n d. [cited 2016 Nov 25]. Available from: http://www.who.int/csr/research-and-development/mers-landscape.pdf
   Google Scholar